Latest News and Press Releases

SOUTH SAN FRANCISCO, Calif., Sept. 26, 2019 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq: MYOK), today announced that Taylor Harris, Chief Financial Officer, will participate in a fireside chat at...

SOUTH SAN FRANCISCO, Calif., Sept. 10, 2019 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq: MYOK), today announced that it will study mavacamten as a therapeutic alternative to septal reduction therapy...

Durability of Mavacamten's Safety and Efficacy Profile Demonstrated through Nine Months in this Study of Patients with Symptomatic, Obstructive HCM Statistically Significant Changes in Key Biomarkers...

SOUTH SAN FRANCISCO, Calif., Aug. 28, 2019 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq: MYOK), today announced its participation in the following upcoming investor conferences: Citi 14th Annual...

SOUTH SAN FRANCISCO, Calif., Aug. 26, 2019 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq: MYOK) today announced the presentation of three abstracts at the upcoming European Society of Cardiology (ESC)...

SOUTH SAN FRANCISCO, Calif., Aug. 21, 2019 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq: MYOK) today announced that it has dosed the first subjects in a Phase 1 clinical study of MYK-224, a small...

SOUTH SAN FRANCISCO, Calif., Aug. 15, 2019 (GLOBE NEWSWIRE) -- MyoKardia, Inc. today announced the launch of the 2nd Annual MyoSeeds™ Research Grants Program, an initiative to support original,...

Announces Last Patient to be Enrolled in EXPLORER-HCM Phase 3 during the Week of August 12th; Topline Data Accelerated to 2nd Quarter 2020 Topline Phase 2 Clinical Data from MAVERICK-HCM and MYK-491...

SOUTH SAN FRANCISCO, Calif., Aug. 07, 2019 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq: MYOK), today announced that Taylor Harris, Chief Financial Officer, will present at the 2019 Wedbush PacGrow...

SOUTH SAN FRANCISCO, Calif., July 31, 2019 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq: MYOK), today announced that it will report second quarter 2019 financial and operating results on Wednesday,...